Auraptene Pharmacology in Cancer and Neuroprotection

Auraptene is a naturally occurring prenylated coumarin predominantly isolated from citrus species. In oncology, it has emerged as a multitargeted agent capable of modulating key signalling pathways that govern cell proliferation, apoptosis and angiogenesis. Preclinical studies report its capacity to induce cell-cycle arrest, enhance detoxifying enzymes and suppress tumour-promoting transcription factors. In the central nervous system, auraptene exhibits anti-inflammatory and antioxidant properties, attenuating microglial activation and protecting neuronal networks from excitotoxic or ischaemic injury. Its lipophilicity permits penetration of the blood–brain barrier, enabling direct interaction with glial cells and neurons. Collectively, these attributes position auraptene as a promising dual-action compound for chemoprevention and neuroprotection, with translational potential in cancer therapy and the mitigation of neurodegenerative processes.

Research from Nature Portfolio

A comprehensive meta-analysis has synthesised data from numerous in vitro studies to quantify auraptene’s anticancer efficacy. Findings demonstrate a clear dose-dependent reduction in viability across a range of human cancer cell lines, establishing robust cytotoxicity profiles. Comparative assessment with a related prenyloxycoumarin revealed that additional isoprenylation may enhance membrane permeability and potency. Advanced statistical modelling highlighted the influence of coumarin dose and tumour type on therapeutic response, while structural insights into lipid solubility inform the design of next-generation analogues. These results consolidate auraptene’s status as a candidate for further preclinical evaluation and early-phase clinical investigation.

Auraptene Pharmacology in Cancer and Neuroprotection publication trend

The graph below shows the total number of articles in auraptene pharmacology in cancer and neuroprotection across all publications each year (not limited to Nature Index journals).

Technical terms

Prenylated coumarin: A coumarin derivative bearing a lipophilic isoprenoid side chain that enhances cellular uptake and bioactivity.

Cytotoxicity: The ability of a compound to kill or inhibit the growth of cells, commonly assessed in tumour cell assays.

Microglial activation: The process by which resident immune cells of the brain adopt a pro-inflammatory phenotype in response to injury or insult.

Apoptosis: Programmed cell death characterised by specific biochemical and morphological changes, essential for tissue homeostasis.

Blood–brain barrier: A selective vascular interface that regulates the passage of molecules from the circulation into the central nervous system.

References

1. Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis. Scientific Reports (2024).
2. A Review of Auraptene as an Anticancer Agent. Frontiers in Pharmacology (2021).
3. Auraptene and Other Prenyloxyphenylpropanoids Suppress Microglial Activation and Dopaminergic Neuronal Cell Death in a Lipopolysaccharide-Induced Model of Parkinson’s Disease. International Journal of Molecular Sciences (2016).
4. Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats. BMC Cancer (2009).